Psoriasis is a chronic, immune-mediated, inflammatory condition that affects a significant portion of the global population [4, 6]. Because it is a multisystem disease, untreated or subclinical inflammation can extend beyond the skin, impacting joints, muscles, and internal organs such as the heart, liver, and kidneys [6]. Furthermore, psoriasis is associated with various health complications, including cardiovascular issues and psoriatic arthritis, which affects roughly one-third of individuals with the condition [7, 8]. Understanding the full spectrum of treatment options—ranging from traditional approaches to advanced biologic therapies—is essential for long-term health and disease management.
The Evolution of Systemic Therapies and Biologics
The therapeutic landscape for moderate-to-severe psoriasis has expanded substantially due to a deeper understanding of the disease's underlying mechanisms [2]. Modern medical options now include sophisticated biologic drugs that are administered via subcutaneous, intramuscular, or intravenous routes [1]. These targeted biologic treatments include tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-23 inhibitors, and ustekinumab, which targets both IL-12 and IL-23 [2]. Clinical trials and real-world safety data help dermatologists personalize these potent medications to fit individual patient profiles, ensuring optimal management of both skin manifestations and associated conditions [2]. While these parenteral options require careful clinical integration [1], they offer a pathway to clear skin and a better quality of life even for patients with severe disease [8].
Personalizing Treatment for Comorbidities
Managing psoriasis effectively requires a comprehensive evaluation of concurrent medical conditions. Current treatment algorithms are designed to guide clinicians when patients present with complex health backgrounds, such as psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, congestive heart failure, hepatitis B, latent tuberculosis, lymphoma, or nonmelanoma skin cancer [2]. Because disease progression can be unpredictable—shifting from mild plaque formation to widespread moderate-to-severe disease—early and appropriate intervention is crucial [6]. Dermatologists carefully weigh the benefits and disadvantages of first-line biologics to safeguard patient health while addressing both cutaneous symptoms and systemic inflammation [2].
Integrating Lifestyle and Integrative Approaches
In addition to conventional medical treatments, integrative dermatology explores how lifestyle factors influence psoriasis severity and overall well-being [3]. Modifications in diet, body composition, exercise, sleep hygiene, and stress management do not replace conventional pharmaceutical care, but rather work alongside it [3]. Adopting healthy lifestyle habits can potentially enhance treatment response, help mitigate underlying risk factors, and simultaneously address serious medical comorbidities, allowing patients to take an active role in their long-term health plan [3].
Sources
- [1] Practical considerations in future psoriasis therapies.
- [2] Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
- [3] Integrative dermatology for psoriasis: facts and controversies.
- [4] Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
- [6] The Importance of Early Treatment in Psoriasis and Management of Disease Progression.
- [7] Psoriatic arthritis for the dermatologist.
- [8] Psoriasis--new insights into pathogenesis and treatment.